Archives

FORUS and PharmaEssentia Have Entered Into an Exclusive Licensing Agreement for The Registration and Distribution of BESREMi® for The Treatment of polycythemia vera (PV), in Canada

Nov 6, 2024

FORUS Therapeutics Inc. and PharmaEssentia Corporation have entered into an exclusive licensing agreement for the registration and distribution of BESREMi® (ropeginterferon alfa-2b) for the treatment of polycythemia vera (PV), in Canada. Under the terms of the...

Accessibility by WAH

FORUS and PharmaEssentia Have Entered Into an Exclusive Licensing Agreement for The Registration and Distribution of BESREMi® for The Treatment of polycythemia vera (PV), in Canada

Recent Posts

Recent Comments

Categories

Meta